Developed by Shray Alag, The Harker School
Sections: Correlations,
Clinical Trials, and HPO
Navigate: Clinical Trials and HPO
| Name (Synonyms) | Correlation | |
|---|---|---|
| drug416 | Awake proning Wiki | 1.00 |
| drug2981 | Placebo oral tablet Wiki | 0.18 |
Navigate: Correlations HPO
There is one clinical trial.
COVID-19 was declared a pandemic on March 11th. Efforts to save lives are essential as we will face increasing morbidity with rising demands on health care resources. Since pregnant women with COVID-19 have systematically been excluded from drug trials, potential treatment options for these high-risk individuals remain untested. The aim of our trial is to determine whether hydroxychloroquine given to COVID-19 positive pregnant women can reduce COVID-19-related hospital admissions, thereby allowing women to stay at home while limiting utilization of hospital resources and resulting exposure of health care providers.
Description: COVID-19-related hospital admissions will be reported by the participants throughout pregnancy until delivery.
Measure: COVID-19-related hospital admissions Time: Hospital Admission at any point from study enrollment to deliveryDescription: Measurement of reported symptoms using a validated questionnaire on Day 3, 7, 10, and every 2 weeks. The FLU-PRO Questionnaire instructs respondents to rate the severity of 37 influenza symptoms over the past 24 hours, including those related to the nose, throat, eye, chest, head, stomach, fatigue, and body aches/pains. For 32 of 37 items, respondents rated the severity of each symptom on 5-point Likert-type scales from 0 ("Not at all), 1 ("A little bit"), 2 ("Somewhat"), 3 ("Quite a bit"), to 4 ("Very much"). For the five remaining items, severity is expressed as frequency of occurrence: vomiting or diarrhea (0 times, 1 time, 2 times, 3 times, or 4 or more times), and sneezing, coughing, and coughed up mucus or phlegm on a scale from 0 ("Never") to 4 ("Always"), with higher scores indicating more severe symptoms.
Measure: Symptoms related to COVID-19 infection Time: Participants will be contacted at day 3, 7, and 10 post-randomization, and every 2 weeks up to to deliveryDescription: Side effects related to hydroxychloqoruine
Measure: Adverse Events Time: Participants will be contacted at day 3, 7, and 10 post-randomization, and every 2 weeks up to to deliveryDescription: Type of delivery (elective non-urgent cesarean, elective urgent cesarean section, non-elective cesarean within labor, instrumental vaginal, spontaneous vaginal)
Measure: Maternal outcomes Time: Participants will be contacted within 2 weeks after delivery to obtain information about their labor and delivery.Description: If had cesarean delivery, indication for cesarean section
Measure: Maternal outcomes Time: Participants will be contacted within 2 weeks after delivery to obtain information about their labor and delivery.Description: Miscarriage or stillbirth (Yes/No)
Measure: Maternal outcomes Time: Participants will be contacted within 2 weeks after delivery to obtain information about their labor and delivery.Description: Labor induction or augmentation (Yes/No) and indication
Measure: Maternal outcomes Time: Participants will be contacted within 2 weeks after delivery to obtain information about their labor and delivery.Description: Epidural use (Yes/No)
Measure: Maternal outcomes Time: Participants will be contacted within 2 weeks after delivery to obtain information about their labor and delivery.Description: Gestational age at delivery (weeks)
Measure: Newborn outcomes Time: Participants will be contacted within 2 weeks after delivery to obtain information about their baby.Description: Sex (female/male)
Measure: Newborn outcomes Time: Participants will be contacted within 2 weeks after delivery to obtain information about their baby.Description: Birth weight (kg) Birth weight (kg)
Measure: Newborn outcomes Time: Participants will be contacted within 2 weeks after delivery to obtain information about their baby.Description: Need for resuscitation (Yes/No)
Measure: Newborn outcomes Time: Participants will be contacted within 2 weeks after delivery to obtain information about their baby.Description: NICU admission (Yes/No)
Measure: Newborn outcomes Time: Participants will be contacted within 2 weeks after delivery to obtain information about their baby.Description: Medical conditions (jaundice, IVH, RDS, pneumothorax, PDA, NEC)
Measure: Newborn outcomes Time: Participants will be contacted within 2 weeks after delivery to obtain information about their baby.Description: Current disposition of baby (home or hospital)
Measure: Newborn outcomes Time: Participants will be contacted within 2 weeks after delivery to obtain information about their baby.Alphabetical listing of all HPO terms. Navigate: Correlations Clinical Trials
Data processed on September 26, 2020.
An HTML report was created for each of the unique drugs, MeSH, and HPO terms associated with COVID-19 clinical trials. Each report contains a list of either the drug, the MeSH terms, or the HPO terms. All of the terms in a category are displayed on the left-hand side of the report to enable easy navigation, and the reports contain a list of correlated drugs, MeSH, and HPO terms. Further, all reports contain the details of the clinical trials in which the term is referenced. Every clinical trial report shows the mapped HPO and MeSH terms, which are also hyperlinked. Related HPO terms, with their associated genes, protein mutations, and SNPs are also referenced in the report.
Drug Reports MeSH Reports HPO Reports